В любое время 18% населения мира могут испытывать боль в нижней части спины, а 38% людей будут испытывать такую боль в течение 1 года. Боль в спине относится к числу очень дорогостоящих нарушений здоровья. После острого эпизода боли в нижней части спины 1/3 пациентов испытывают повторный эпизод, и примерно 1/2 из них обратятся за медицинской помощью. В статье представлены основные причины боли в спине и принципы терапии. На сегодняшний день приоритетным направлением ведения больного с болью в спине является максимально раннее купирование болевого синдрома. Для купирования острой боли в спине наиболее широкое применение получили нестероидные противовоспалительные препараты. С этой целью применяют как селективные ингибиторы циклооксигеназы 2-го типа, так и неселективные ингибиторы циклооксигеназы двух типов. Представлены преимущества назначения при боли в спине нимесулида (Найза) – представителя класса селективных ингибиторов циклооксигеназы-2.
Ключевые слова: боль в спине, эпидемиология, причины боли в спине, лечение, нестероидные противовоспалительные препараты, нимесулид (Найз).
________________________________________________
At any time, 18% of the world's population may experience pain in the lower back, and 38% of people will experience such pain within 1 year. Back pain is one of the most costly health problems. After an acute episode of pain in the lower back, 1/3 of patients experience a second episode, and approximately 1/2 of them will seek medical help. The article presents the main causes of back pain and the principles of therapy. To date, the priority direction of patient management with pain in the back is the earliest possible relief of pain syndrome. For the relief of acute back pain, non-steroidal anti-inflammatory drugs have been most widely used. To this end, both selective inhibitors of cyclooxygenase type 2 and nonselective inhibitors of cyclooxygenase of two types are used. Advantages of administration of nimesulide (Nise), a representative of the class of selective inhibitors of cyclooxygenase-2, are presented.
Key words: back pain, epidemiology, causes of back pain, treatment, non-steroidal anti-inflammatory drugs, nimesulide (Nise).
1. Hoy D, Bain C, Williams G et al. A systematic review of the global prevalence of low back pain. Arthritis Rheum 2012; 64 (6): 2028–37.
2. Vos T, Flaxman AD, Naghavi M et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859): 2163–96.
3. Machado GC, Maher CG, Ferreira PH et al. Can Recurrence After an Acute Episode of Low Back Pain Be Predicted? Phys Ther 2017; 97 (9): 889–95. DOI: 10.1093/ptj/pzx067
4. Hoy D, Brooks P, Blyth F, Buchbinder R. The Epidemiology of low back pain. Best Pract Res Clin Rheumatol 2010; 24 (6): 769–81. DOI: 10.1016/j.berh.2010.10.002
5. Hayden JA, Chou R, Hogg-Johnson S, Bombardier C. Systematic reviews of low back pain prognosis had variable methods and results: guidance for future prognosis reviews.
J Clin Epidemiol 2009; 62 (8): 781–96.
6. Wertli MM, Rasmussen-Barr E, Weiser S et al. The role of fear avoidance beliefs as a prognostic factor for outcome in patients with nonspecific low back pain: a systematic review. Spine 2014; 14 (5): 816–36.
7. Hall AM, Kamper SJ, Maher CG et al. Symptoms of depression and stress mediate the effect of pain on disability. Pain 2011; 152 (5): 1044–51.
8. Boer MJ, Struys MM, Versteegen GJ. Pain-related catastrophizing in pain patients and people with pain in the general population. Eur J Pain 2012; 16 (7): 1044–52.
9. Velasco Garrido M, Bittner C, Harth V, Preisser A. Health status and health-related quality of life of municipal waste collection workers - a cross-sectional survey. J Occup Med Toxicol 2015; 8: 10–22.
10. Dagenais S, Caro J, Haldeman S. A systematic review of low back pain cost of illness studies in the United States and internationally. Spine J 2008; 8 (1): 8–20.
11. Wieser S, Horisberger B, Schmidhauser S et al. Cost of low back pain in Switzerland in 2005. Eur J Health Econ 2011; 12 (5): 455–67.
12. Dagenais S, Caro J, Haldeman S. A systematic review of low back pain cost of illness studies in the United States and internationally. Spine J 2008; 8 (1): 8–20.
13. Котова О.В., Акарачкова Е.С., Данилов А.Б. Вопросы длительной терапии болевых синдромов. Рус. мед. журн. 2015; 23 (30): 16–8. / Kotova O.V., Akarachkova E.S., Danilov A.B. Voprosy dlitel'noi terapii bolevykh sindromov. Rus. med. zhurn. 2015; 23 (30): 16–8. [in Russian]
14. Левин О.С. Диагностика и лечение неврологических проявлений остеохондроза позвоночника. Consilium Medicum. 2004; 6 (8). / Levin O.S. Diagnostika i lechenie nevrologicheskikh proiavlenii osteokhondroza pozvonochnika. Consilium Medicum. 2004; 6 (8). [in Russian]
15. Справочник по формулированию клинического диагноза болезней нервной системы. Под ред. В.Н.Штока, О.С.Левина. М.: МИА, 2006. / Spravochnik po formulirovaniiu klinicheskogo diagnoza boleznei nervnoi sistemy. Pod red. V.N.Shtoka, O.S.Levina. M.: MIA, 2006. [in Russian]
16. Никифоров А.С., Авакян Г.Н., Мендель О.И. Неврологические осложнения остеохондроза позвоночника. М.: ГЭОТАР-Медиа, 2015. / Nikiforov A.S., Avakian G.N., Mendel' O.I. Nevrologicheskie oslozhneniia osteokhondroza pozvonochnika. M.: GEOTAR-Media, 2015. [in Russian]
17. Котова О.В. Острая боль в нижней части спины: не дать болезни затянуться. Фарматека. 2012; 14 (247): 60–4. / Kotova O.V. Ostraia bol' v nizhnei chasti spiny: ne dat' bolezni zatianut'sia. Farmateka. 2012; 14 (247): 60–4. [in Russian]
18. Прокопенко С.В., Исаева Н.В., Шанина Е.Г. Диагностика и лечение боли в спине у пациентов с коморбидной патологией. РМЖ. 2017; 24: 1593–8. / Prokopenko S.V., Isaeva N.V., Shanina E.G. Diagnostika i lechenie boli v spine u patsientov s komorbidnoi patologiei. RMZh. 2017; 24: 1593–8. [in Russian]
19. Левин О.С., Штульман Д.Р. Неврология: справочник практ. врача. Изд. 9-е, доп. и перераб. М.: Медпресс-информ, 2013; с. 183–200. / Levin O.S., Shtul'man D.R. Nevrologiia: spravochnik prakt. vracha. Izd. 9-e, dop. i pererab. M.: Medpress-inform, 2013; s. 183–200. [in Russian]
20. Подчуфарова Е.В., Яхно Н.Н. Боли в спине и конечностях. Болезни нервной системы. Руководство для врачей. М., 2005. / Podchufarova E.V., Iakhno N.N. Boli v spine i konechnostiakh. Bolezni nervnoi sistemy. Rukovodstvo dlia vrachei. M., 2005. [in Russian]
21. Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: ИМА-ПРЕСС, 2009. / Karateev A.E., Iakhno N.N., Lazebnik L.B. i dr. Primenenie nesteroidnykh protivovospalitel'nykh preparatov. Klinicheskie rekomendatsii. M.: IMA-PRESS, 2009. [in Russian]
22. Samad TA, Moore KA, Sapirstein A et al. Interleukin-1 beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001; 410 (6827): 471–5.
23. Malmberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 1992; 257 (5074): 1276–9.
24. Yamamoto T, Sakashita Y. COX-2 inhibitor prevents the development of hyperalgesia induced by intrathecal NMDA or AMPA. Neuroreport 1998; 9 (17): 3869–73.
25. Euchenhofer C, Maihófner C, Brune K et al. Differential effect of selective cyclooxygenase-2 (COX-2) inhibitor NS 398 and diclofenac on formalin-induced nociception in the rat. Neurosci Lett 1998; 248 (1): 25–8.
26. Telleria-Diaz A, Schmidt M, Kreusch S et al. Spinal antinociceptive effects of cyclooxygenase inhibition during inflammation: Involvement of prostaglandins and endocannabinoids. Pain 2010; 148 (1): 26–35.
27. Котова О.В., Акарачкова Е.С. Нимесулид: эффективность и безопасность применения. Consilium Medicum. 2016; 18 (2): 100–3. / Kotova O.V., Akarachkova E.S. Nimesulide: efficacy and safety. Consilium Medicum. 2016; 18 (2): 100–3. [in Russian]
28. Котова О.В. Боль в спине: предотвратить хронизацию. РМЖ. 2011; 30: 1872–3. / Kotova O.V. Bol' v spine: predotvratit' khronizatsiiu. RMZh. 2011; 30: 1872–3. [in Russian]
29. Pohjolainen T, Jekunen A, Autio L, Vuorela H. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine 2000; 25 (12): 1579–85.
________________________________________________
1. Hoy D, Bain C, Williams G et al. A systematic review of the global prevalence of low back pain. Arthritis Rheum 2012; 64 (6): 2028–37.
2. Vos T, Flaxman AD, Naghavi M et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859): 2163–96.
3. Machado GC, Maher CG, Ferreira PH et al. Can Recurrence After an Acute Episode of Low Back Pain Be Predicted? Phys Ther 2017; 97 (9): 889–95. DOI: 10.1093/ptj/pzx067
4. Hoy D, Brooks P, Blyth F, Buchbinder R. The Epidemiology of low back pain. Best Pract Res Clin Rheumatol 2010; 24 (6): 769–81. DOI: 10.1016/j.berh.2010.10.002
5. Hayden JA, Chou R, Hogg-Johnson S, Bombardier C. Systematic reviews of low back pain prognosis had variable methods and results: guidance for future prognosis reviews.
J Clin Epidemiol 2009; 62 (8): 781–96.
6. Wertli MM, Rasmussen-Barr E, Weiser S et al. The role of fear avoidance beliefs as a prognostic factor for outcome in patients with nonspecific low back pain: a systematic review. Spine 2014; 14 (5): 816–36.
7. Hall AM, Kamper SJ, Maher CG et al. Symptoms of depression and stress mediate the effect of pain on disability. Pain 2011; 152 (5): 1044–51.
8. Boer MJ, Struys MM, Versteegen GJ. Pain-related catastrophizing in pain patients and people with pain in the general population. Eur J Pain 2012; 16 (7): 1044–52.
9. Velasco Garrido M, Bittner C, Harth V, Preisser A. Health status and health-related quality of life of municipal waste collection workers - a cross-sectional survey. J Occup Med Toxicol 2015; 8: 10–22.
10. Dagenais S, Caro J, Haldeman S. A systematic review of low back pain cost of illness studies in the United States and internationally. Spine J 2008; 8 (1): 8–20.
11. Wieser S, Horisberger B, Schmidhauser S et al. Cost of low back pain in Switzerland in 2005. Eur J Health Econ 2011; 12 (5): 455–67.
12. Dagenais S, Caro J, Haldeman S. A systematic review of low back pain cost of illness studies in the United States and internationally. Spine J 2008; 8 (1): 8–20.
13. Kotova O.V., Akarachkova E.S., Danilov A.B. Voprosy dlitel'noi terapii bolevykh sindromov. Rus. med. zhurn. 2015; 23 (30): 16–8. [in Russian]
14. Levin O.S. Diagnostika i lechenie nevrologicheskikh proiavlenii osteokhondroza pozvonochnika. Consilium Medicum. 2004; 6 (8). [in Russian]
15. Spravochnik po formulirovaniiu klinicheskogo diagnoza boleznei nervnoi sistemy. Pod red. V.N.Shtoka, O.S.Levina. M.: MIA, 2006. [in Russian]
16. Nikiforov A.S., Avakian G.N., Mendel' O.I. Nevrologicheskie oslozhneniia osteokhondroza pozvonochnika. M.: GEOTAR-Media, 2015. [in Russian]
17. Kotova O.V. Ostraia bol' v nizhnei chasti spiny: ne dat' bolezni zatianut'sia. Farmateka. 2012; 14 (247): 60–4. [in Russian]
18. Prokopenko S.V., Isaeva N.V., Shanina E.G. Diagnostika i lechenie boli v spine u patsientov s komorbidnoi patologiei. RMZh. 2017; 24: 1593–8. [in Russian]
19. Levin O.S., Shtul'man D.R. Nevrologiia: spravochnik prakt. vracha. Izd. 9-e, dop. i pererab. M.: Medpress-inform, 2013; s. 183–200. [in Russian]
20. Podchufarova E.V., Iakhno N.N. Boli v spine i konechnostiakh. Bolezni nervnoi sistemy. Rukovodstvo dlia vrachei. M., 2005. [in Russian]
21. Karateev A.E., Iakhno N.N., Lazebnik L.B. i dr. Primenenie nesteroidnykh protivovospalitel'nykh preparatov. Klinicheskie rekomendatsii. M.: IMA-PRESS, 2009. [in Russian]
22. Samad TA, Moore KA, Sapirstein A et al. Interleukin-1 beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001; 410 (6827): 471–5.
23. Malmberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 1992; 257 (5074): 1276–9.
24. Yamamoto T, Sakashita Y. COX-2 inhibitor prevents the development of hyperalgesia induced by intrathecal NMDA or AMPA. Neuroreport 1998; 9 (17): 3869–73.
25. Euchenhofer C, Maihófner C, Brune K et al. Differential effect of selective cyclooxygenase-2 (COX-2) inhibitor NS 398 and diclofenac on formalin-induced nociception in the rat. Neurosci Lett 1998; 248 (1): 25–8.
26. Telleria-Diaz A, Schmidt M, Kreusch S et al. Spinal antinociceptive effects of cyclooxygenase inhibition during inflammation: Involvement of prostaglandins and endocannabinoids. Pain 2010; 148 (1): 26–35.
27. Kotova O.V., Akarachkova E.S. Nimesulide: efficacy and safety. Consilium Medicum. 2016; 18 (2): 100–3. [in Russian]
28. Kotova O.V. Bol' v spine: predotvratit' khronizatsiiu. RMZh. 2011; 30: 1872–3. [in Russian]
29. Pohjolainen T, Jekunen A, Autio L, Vuorela H. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine 2000; 25 (12): 1579–85.
Авторы
О.В.Котова*1, Е.С.Акарачкова1,2
1 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2;
2 Международное общество «Стресс под контролем». 115573, Россия, Москва, ул. Мусы Джалиля, д. 40 *ol_kotova@mail.ru
________________________________________________
O.V.Kotova*1, E.S.Akarachkova1,2
1 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2;
2 International Society “Stress under control”. 115573, Russian Federation, Moscow, ul. Musy Dzhalilya, d. 40 *ol_kotova@mail.ru